India, Aug. 4 -- Rhythm Pharmaceuticals, Inc. (RYTM) announced preliminary results from its ongoing Phase 2 trial of RM-718, an investigational once-weekly MC4R agonist, in patients with acquired hypothalamic obesity.
Acquired hypothalamic obesity (HO) is a rare condition that occurs when the hypothalamus-the part of the brain that regulates hunger and energy balance- is damaged, often following brain tumors, surgery, or trauma. Patients experience rapid, severe weight gain that is resistant to lifestyle interventions, leaving few effective treatment options.
The study enrolled 11 patients, with 7 reaching 16 weeks of treatment. Interim findings showed a mean BMI reduction of 11.6% from baseline, a magnitude consistent with Rhythm's appro...